Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a custom tumor map guide better ovarian cancer care?

NCT ID NCT06466382

Knowledge-focused Sponsor: Swiss GO Trial Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Swiss study is testing whether creating a detailed molecular profile of each patient's tumor can help doctors choose more effective treatments for advanced ovarian cancer. Sixty newly diagnosed patients will be randomly assigned to either standard care or a personalized treatment plan recommended by a molecular tumor board. The goal is to see if this tailored approach leads to better tumor response and helps doctors feel more confident in their treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
molecular tumor board recommendation based on tumor profiling
What this could lead to
If successful, this could show that personalized treatment plans based on detailed tumor analysis improve outcomes for ovarian cancer patients who don't respond to standard therapy.
What could go wrong
This is a small pilot study (60 participants) focused on feasibility and early signals, not a large-scale test of effectiveness. The approach may not lead to better survival or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV * No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis * Envisaged surgical candidate for interval debulking after 2 cycles of treatment * Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures * ECOG 0-2 * Written informed consent according to national legal and regulatory requirements prior to any project specific procedures Exclusion Criteria: * Elevated liver enzymes (double of normal range: ASAT \> 68 U/l; ALAT \> 82 U/l; GGT \> 80 U/l) * Elevated creatinine (double of normal range: \>120 mmol/l)) * ECOG ≥3 * Pregnant or lactating women * Any other malignancy within the last 5 years which has an impact on the prognosis of the patient * Inability to swallow tablets * Concurrent participation in another clinical trial on the same indication * Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinosarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinosarcoma fallopian tube neoplasm ovarian endometrioid adenocarcinoma ovarian epithelial tumor ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fallopian tube neoplasms High-grade serous ovarian carcinoma (hgsoc) Ovarian endometrioid carcinoma Ovarian neoplasm epithelial

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • HFR-Fribourg- Hopital Cantonal

    RECRUITING

    Fribourg, 1708, Switzerland

  • HOCH Health Ostschweiz Kantonsspital St.Gallen

    RECRUITING

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

  • Inselspital Bern (University Hospital for Medical Oncology)

    RECRUITING

    Bern, 3010, Switzerland

  • Kantonsspital Baden AG

    RECRUITING

    Baden, Canton of Aargau, 5404, Switzerland

  • Thurgau AG Frauenfeld / Münsterlingen

    RECRUITING

    Frauenfeld, Thurgau, 8500, Switzerland

  • University Hospital Zurich

    RECRUITING

    Zurich, 8091, Switzerland

  • Universitätsspital Basel

    RECRUITING

    Basel, Canton of Basel-City, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.